-+ 0.00%
-+ 0.00%
-+ 0.00%

Changchun Hi-Tech announced on August 31. Recently, Changchun Jinsai Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci 161 injection was accepted. GenScI 161 injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is intended to be used to treat connective tissue disease-related interstitial lung diseases.

Zhitongcaijing·08/31/2026 11:33:19
Listen to the news
Changchun Hi-Tech announced on August 31. Recently, Changchun Jinsai Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci 161 injection was accepted. GenScI 161 injection is a therapeutic biological product class 1 drug independently developed by Jinsai Pharmaceutical. It is intended to be used to treat connective tissue disease-related interstitial lung diseases.